

ESM table 1. Changes in body weight, low density lipoproteins, high density lipoproteins, triglycerides and total cholesterol at the end of 12 weeks.

	Placebo Group (n = 62)	75µg (n = 62)	150µg (n = 63)	200µg (n = 63)
Body weight (kg)				
LSM (95% CI)	-0.67 (-1.25, -0.09)	-0.89 (-1.47, -0.31)	-0.67 (-1.24, -0.10)	-1.48 (-2.06, -0.91)
P value of four groups			0.154	
LSMD compared with placebo (95% CI)		-0.22 (-1.04, 0.60)	0.00 (-0.82, 0.82)	-0.82 (-1.62, -0.01)
P value compared with placebo group		0.594	>0.999	0.047
LSMD compared with 75-µg group (95% CI)			0.22 (-0.58, 1.03)	-0.59 (-1.42, 0.23)
P value compared with 75-µg group			0.22 (-0.58, 1.03)	-0.59 (-1.42, 0.23)
LSMD compared with 150-µg group (95% CI)				-0.82 (-1.63, -0.00)
P value compared with 150-µg group				0.050
Total cholesterol (mmol/L)				
LSM (95% CI)	0.07 (-0.10, 0.24)	-0.14 (-0.31, 0.04)	-0.27 (-0.44, -0.10)	-0.36 (-0.53, -0.19)
P value of four groups			0.004	
LSMD compared with placebo (95% CI)		-0.21 (-0.45, 0.04)	-0.34 (-0.58, -0.09)	-0.43 (-0.67, -0.19)

<i>P</i> value compared with placebo group	0.102	0.007	<0.001
LSMD compared with 75-μg group (95% CI)		−0.13 (−0.37, 0.11)	−0.23 (−0.47, 0.02)
<i>P</i> value compared with 75-μg group		0.275	0.073
LSMD compared with 150-μg group (95% CI)			−0.09 (−0.34, 0.15)
<i>P</i> value compared with 150-μg group			0.450
Triglycerides (mmol/L)			
LSM (95% CI)	0.32 (−0.05, 0.68)	0.08 (−0.28, 0.44)	−0.26 (−0.61, 0.10)
<i>P</i> value of four groups		0.061	
LSMD compared with placebo (95% CI)	−0.24 (−0.75, 0.28)	−0.57 (−1.09, −0.06)	−0.60 (−1.11, −0.09)
<i>P</i> value compared with placebo group	0.365	0.028	0.021
LSMD compared with 75-μg group (95% CI)		−0.34 (−0.84, 0.17)	−0.36 (−0.88, 0.15)
<i>P</i> value compared with 75-μg group		0.189	0.168

LSMD compared with 150-μg group (95% CI)					-0.03 (-0.54, 0.49)
--	--	--	--	--	---------------------

<i>P</i> value compared with 150-μg group					0.919
---	--	--	--	--	-------

High density lipoproteins (mmol/L)

LSM (95% CI)	0.02 (-0.03, 0.06)	0.03 (-0.02, 0.07)	0.02 (-0.02, 0.07)	-0.01 (-0.06, 0.03)
--------------	--------------------	--------------------	--------------------	---------------------

<i>P</i> value of four groups					0.582
-------------------------------	--	--	--	--	-------

LSMD compared with placebo (95% CI)		0.01 (-0.05, 0.07)	0.01 (-0.06, 0.07)	(-0.09, 0.03)
-------------------------------------	--	--------------------	--------------------	---------------

<i>P</i> value compared with placebo group		0.757	0.840	0.326
--	--	-------	-------	-------

LSMD compared with 75-μg group (95% CI)			-0.00 (-0.07, 0.06)	-0.04 (-0.10, 0.02)
---	--	--	---------------------	---------------------

<i>P</i> value compared with 75-μg group			0.914	0.211
--	--	--	-------	-------

LSMD compared with 150-μg group (95% CI)				-0.04 (-0.10, 0.03)
--	--	--	--	---------------------

<i>P</i> value compared with 150-μg group				0.251
---	--	--	--	-------

Low density lipoproteins (mmol/L)

LSM (95% CI)	-0.02 (-0.15, 0.10)	-0.19 (-0.31, -0.06)	-0.12 (-0.24, 0.01)	-0.24 (-0.36, -0.11)
--------------	---------------------	----------------------	---------------------	----------------------

<i>P</i> value of four groups					0.081
-------------------------------	--	--	--	--	-------

LSMD compared with placebo (95% CI)		-0.16 (-0.34, 0.01)	-0.10 (-0.27, 0.08)	-0.22 (-0.39, -0.04)
-------------------------------------	--	---------------------	---------------------	----------------------

<i>P</i> value compared with placebo group	0.068	0.290	0.015
LSMD compared with 75-μg group (95% CI)		0.07 (−0.11, 0.24)	−0.05 (−0.23, 0.13)
<i>P</i> value compared with 75-μg group		0.435	0.572
LSMD compared with 150-μg group (95% CI)			−0.12 (−0.30, 0.06)
<i>P</i> value compared with 150-μg group			0.178

ESM Table 2. Sensitivity analysis for change in HbA_{1c} from baseline to 12 weeks in repeated measurement mixed linear model

	Placebo Group (n = 62)	75µg (n = 62)	150µg (n = 63)	200µg (n = 63)
At 12 weeks				
LSM mmol/mol (95% CI)	−4.26 (−6.55, −2.07)	−13.10 (−15.37, −10.83)	−18.78 (−21.07, −16.37)	−15.50 (−17.79, −13.09)
LSM % (95% CI)	−0.39 (−0.60, −0.18)	−1.21 (−1.42, −1.00)	−1.72 (−1.93, −1.50)	−1.42 (−1.63, −1.20)
LSMD mmol/mol compared with placebo (95% CI)		−8.84 (−12.07, −5.60)	−14.52 (−17.79, −11.24)	−11.24 (−14.51, −7.97)
LSMD % compared with placebo (95% CI)		−0.82 (−1.12, −0.52)	−1.33 (−1.63, −1.03)	−1.03 (−1.33, −0.73)
<i>P</i> value compared with placebo group		<0.001	<0.001	<0.001
LSMD mmol/mol compared with 75-µg group (95% CI)			−5.68 (−9.02, −2.23)	−2.14 (−5.19, −1.01)
LSMD % compared with 75-µg group (95% CI)			−0.51 (−0.81, −0.20)	−0.21 (−0.51, −0.10)
<i>P</i> value compared with 75-µg group			0.001	0.181
LSMD mmol/mol compared with 150-µg group (95% CI)				3.28 (0, 6.56)

LSMD % compared with 150-μg
group (95% CI)

0.30 (−0.00, 0.60)

P value compared with 150-μg
group

0.052

Abbreviations: CI, confidence interval; LSM, lease squared mean; LSMD, least squares mean difference.